SSA
PMVP icon

Schonfeld Strategic Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,292
Closed -$23.6K – 2490
2025
Q2 		$23.6K Sell
22,292
-608
-3% -$596 ﹤0.01% 1927
2025
Q1 		$25K Sell
22,900
-12,300
-35% -$16.7K ﹤0.01% 2100
2024
Q4 		$53.2K Sell
35,200
-31,700
-47% -$50.2K ﹤0.01% 1874
2024
Q3 		$99.7K Sell
66,900
-62,500
-48% -$96.6K ﹤0.01% 1868
2024
Q2 		$210K Sell
129,400
-12,388
-9% -$22.3K ﹤0.01% 1804
2024
Q1 		$241K Hold
141,788
– – ﹤0.01% 1730
2023
Q4 		$440K Buy
141,788
+70,493
+99% +$187K ﹤0.01% 1332
2023
Q3 		$438K Buy
+71,295
New +$490K ﹤0.01% 1237
2022
Q4 		– Sell
-22,275
Closed -$265K – 2916
2022
Q3 		$265K Buy
+22,275
New +$322K ﹤0.01% 2163

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Schonfeld Strategic Advisors's PMVP Position: Q3 2025 in Review

Schonfeld Strategic Advisors sold out of PMV Pharmaceuticals (PMVP) in Q3 2025, closing a stake of 22,292 shares — an estimated $23.6K sold.

Schonfeld Strategic Advisors first reported a position in PMVP in Q3 2022 and held it in 9 quarters. The position peaked at $440K in Q4 2023. 64 funds tracked by Wall St. Rank hold PMVP as of Q3 2025.

  • Schonfeld Strategic Advisors reported no remaining PMV Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 22,292 PMV Pharmaceuticals shares in Q3 2025, an estimated $23.6K.
  • Schonfeld Strategic Advisors first reported a position in PMV Pharmaceuticals in Q3 2022 and held it in 9 quarters.
  • Schonfeld Strategic Advisors's PMV Pharmaceuticals position peaked at $440K in Q4 2023.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.